STATE-OF-THE-ART PAPER
Insulin as an Anti-Inflammatory and Antiatherogenic Modulator
Paresh Dandona, MD, PhD*,*,
Ajay Chaudhuri, MD*,
Husam Ghanim, PhD* and
Priya Mohanty, MD
* Kaleida Health, Buffalo, New York
Division of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo, Buffalo, New York
Manuscript received April 7, 2008;
revised manuscript received October 3, 2008,
accepted October 7, 2008.
* Reprint requests and correspondence: Dr. Paresh Dandona, Diabetes-Endocrinology Center of WNY, 3 Gates Circle, Buffalo, New York 14209 (Email: pdandona{at}kaleidahealth.org).
Data demonstrate the anti-inflammatory effects of insulin and proinflammatory effects of glucose. These data provide a mechanistic justification for the benefits of maintaining euglycemia with insulin infusions in hospitalized patients. Regimens that infuse fixed doses of insulin with high rates of glucose are usually associated with hyperglycemia, which may neutralize the beneficial effects of insulin. Therefore, we propose that such regimens should be avoided and instead replaced by insulin infusions that normalize and maintain blood glucose at a reasonably low level and ensure that plasma insulin is maintained at levels high enough to provide clinically relevant anti-inflammatory and cardioprotective effects. Trials to test this hypothesis are in progress.
Key Words: hyperglycemia acute coronary syndromes diabetes mellitus insulin
|
Abbreviations and Acronyms
| | ACS = acute coronary syndromes | | AMI = acute myocardial infarction | | CABG = coronary artery bypass graft | | CRP = C-reactive protein | | GIK = glucose, insulin, potassium | | ICU = intensive care unit | | NF-kB = nuclear factor-kappa B | | NO = nitric oxide | | SAA = serum amyloid A | | TLR = toll-like receptor |
|
This article has been cited by other articles:

|
 |

|
 |
 
K. W. Ng, M. L. Allen, A. Desai, D. Macrae, and N. Pathan
Cardioprotective Effects of Insulin: How Intensive Insulin Therapy May Benefit Cardiac Surgery Patients
Circulation,
February 7, 2012;
125(5):
721 - 728.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. G. Raimann, A. Kruse, S. Thijssen, V. Kuntsevich, P. Dabel, M. Bachar, J. A. Diaz-Buxo, N. W. Levin, and P. Kotanko
Metabolic effects of dialyzate glucose in chronic hemodialysis: results from a prospective, randomized crossover trial
Nephrol. Dial. Transplant.,
September 22, 2011;
(2011)
gfr520v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Ceriello, K. Esposito, R. Testa, A. R. Bonfigli, M. Marra, and D. Giugliano
The Possible Protective Role of Glucagon-Like Peptide 1 on Endothelium During the Meal and Evidence for an "Endothelial Resistance" to Glucagon-Like Peptide 1 in Diabetes
Diabetes Care,
March 1, 2011;
34(3):
697 - 702.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. M. Younk and S. N. Davis
Hypoglycemia and Vascular Disease
Clin. Chem.,
February 1, 2011;
57(2):
258 - 260.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Lazzeri, S. Valente, M. Chiostri, C. Picariello, and G. F. Gensini
Correlates of acute insulin resistance in the early phase of non-diabetic ST-elevation myocardial infarction
Diabetes and Vascular Disease Research,
January 1, 2011;
8(1):
35 - 42.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J. Wright, D. E. Newby, D. Stirling, C. A. Ludlam, I. A. Macdonald, and B. M. Frier
Effects of Acute Insulin-Induced Hypoglycemia on Indices of Inflammation: Putative mechanism for aggravating vascular disease in diabetes
Diabetes Care,
July 1, 2010;
33(7):
1591 - 1597.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Gunduz, J. Thom, I. Hussain, D. Lopez, F. V. Hartel, A. Erdogan, M. Grebe, D. Sedding, H. M. Piper, H. Tillmanns, et al.
Insulin Stabilizes Microvascular Endothelial Barrier Function via Phosphatidylinositol 3-Kinase/Akt-Mediated Rac1 Activation
Arterioscler Thromb Vasc Biol,
June 1, 2010;
30(6):
1237 - 1245.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. H. Opie and J. Knuuti
The Adrenergic-Fatty Acid Load in Heart Failure
J. Am. Coll. Cardiol.,
October 27, 2009;
54(18):
1637 - 1646.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. D. Pradhan, B. M. Everett, N. R. Cook, N. Rifai, and P. M Ridker
Effects of Initiating Insulin and Metformin on Glycemic Control and Inflammatory Biomarkers Among Patients With Type 2 Diabetes: The LANCET Randomized Trial
JAMA,
September 16, 2009;
302(11):
1186 - 1194.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. J. Pepine
Insulin as a Cardiovascular Therapeutic: Improving Glycemic Control in Patients With Coronary Artery Disease
J. Am. Coll. Cardiol.,
February 3, 2009;
53(5_Suppl_S):
S1 - S2.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Ceriello, S. W. Zarich, and R. Testa
Lowering Glucose to Prevent Adverse Cardiovascular Outcomes in a Critical Care Setting
J. Am. Coll. Cardiol.,
February 3, 2009;
53(5_Suppl_S):
S9 - S13.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|